In addition to trial arm, this post hoc analysis found that the crude rates of AREs differed by age, sex, site, FEV1 Z-score, CD4 count, HIV VL, being on second line ART, history of TB treatment, resistance to azithromycin at baseline, season and calendar year. The gene discussed is CD4; the disease is tuberculosis.